Gen-Probe's Q3 Revenues Inch Up 1 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Gen-Probe reported after the close of the market Thursday that its third-quarter revenues increased 1 percent as clinical diagnostic sales offset weakness in its blood screening business.

The San Diego-based molecular diagnostics firm brought in total revenues of $122.7 million for the three months ended Sept. 30, up from $121.2 million for the third quarter of 2008. Its clinical diagnostic sales for the quarter were $69.6 million, up from $55.5 million, while its blood screening sales dropped to $45.4 million from $52.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.